相关临床试验
0
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- PharmaEssentia will present positive Phase 3 SURPASS-ET trial results showing ropeginterferon alfa-2b-njft achieved significantly higher durable clinical response rates compared to anagrelide (42.9% vs. 6.0%; p=0.0001) in essential thrombocythemia patients. - The trial demonstrated not only effective blood count control but also a measurable reduction in JAK2 mutation allele burden over 12 months, addressing an underlying disease mechanism that current treatments fail to target. - Ropeginterferon alfa-2b-njft (marketed as BESREMi® for polycythemia vera) could potentially offer a new second-line treatment option for essential thrombocythemia, a rare blood disorder characterized by excessive platelet production.
• A Phase 3 trial (SURPASS-ET) is evaluating Ropeginterferon alfa-2b (P1101) versus anagrelide in high-risk essential thrombocythemia (ET) patients intolerant or resistant to hydroxyurea. • The primary endpoint is durable modified European LeukemiaNet composite response at 9 and 12 months. • Initial data from 101 randomized patients across 58 global sites show the trial is proceeding as planned, with no need for intervention identified by the DSMB. • This study could provide the first evidence comparing P1101 with anagrelide, the only approved second-line treatment option for ET.
